Status:
TERMINATED
Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas
Lead Sponsor:
University of Pennsylvania
Conditions:
Gonadotroph Adenomas
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine if administration of pasireotide LAR for one year to three patients with gonadotroph adenomas and elevated serum FSH concentrations will reduce the serum foll...
Detailed Description
Gonadotroph adenomas are the most common pituitary macroadenomas. Currently no medical treatment as been found that decreases the size of these adenomas, so surgery is the only treatment. The reason t...
Eligibility Criteria
Inclusion
- gonadotroph adenoma
Exclusion
- visual impairment attributable to the adenoma
- radiation therapy
- active gallbladder disease
- uncontrolled diabetes
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2011
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT00929669
Start Date
June 1 2009
End Date
November 1 2011
Last Update
November 28 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104